BioSpace News Archive

Elekta announces that its Elekta Unity magnetic resonance radiation therapy system has been awarded the Institute of Physics Business Innovation Award 2019.

Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases

Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members

Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.

Prioritizing Development of SY-5609, Its Oral CDK7 Inhibitor, and Discontinuing Further Development of SY-1365, Its Intravenous CDK7 Inhibitor

Aims to create immune cells with significantly larger DNA payloads encoding synthetic biological instructions to overcome solid tumors’ complex defense systems

Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces that formal arbitration proceedings have been commenced by Elmar R. Burchardt

ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the third quarter ended September 30, 2019 before the U.S. financial markets open on Thursday, October 31, 2019.

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and pharmacodynamics of escalating doses (50mg, 200mg and 400mg) of the investigational compound inarigivir co-administered with Gilead Sciences’ Vemlidy® (tenofovir alafenamide 25mg) for the treatment of chronic hepatitis B virus (HBV) infection.